FibroGen Inc (FGEN)
0.3347
-0.04
(-9.52%)
USD |
NASDAQ |
Nov 15, 16:00
0.3313
0.00 (0.00%)
After-Hours: 20:00
FibroGen Research and Development Expense (TTM): 185.40M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 185.40M |
March 31, 2024 | 246.77M |
December 31, 2023 | 282.86M |
September 30, 2023 | 292.79M |
June 30, 2023 | 306.77M |
March 31, 2023 | 282.26M |
December 31, 2022 | 296.79M |
September 30, 2022 | 349.08M |
June 30, 2022 | 349.78M |
March 31, 2022 | 401.38M |
December 31, 2021 | 387.04M |
September 30, 2021 | 351.26M |
June 30, 2021 | 333.85M |
March 31, 2021 | 272.70M |
December 31, 2020 | 252.92M |
September 30, 2020 | 231.59M |
June 30, 2020 | 223.08M |
March 31, 2020 | 213.67M |
December 31, 2019 | 209.26M |
September 30, 2019 | 222.75M |
June 30, 2019 | 229.23M |
Date | Value |
---|---|
March 31, 2019 | 229.36M |
December 31, 2018 | 235.84M |
September 30, 2018 | 218.02M |
June 30, 2018 | 211.92M |
March 31, 2018 | 206.76M |
December 31, 2017 | 196.52M |
September 30, 2017 | 194.66M |
June 30, 2017 | 184.88M |
March 31, 2017 | 190.29M |
December 31, 2016 | 187.21M |
September 30, 2016 | 196.52M |
June 30, 2016 | 208.04M |
March 31, 2016 | 207.20M |
December 31, 2015 | 214.09M |
September 30, 2015 | 205.42M |
June 30, 2015 | 193.97M |
March 31, 2015 | 175.68M |
December 31, 2014 | 150.79M |
September 30, 2014 | 128.97M |
June 30, 2014 | 111.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
185.40M
Minimum
Jun 2024
401.38M
Maximum
Mar 2022
287.86M
Average
282.86M
Median
Dec 2023
Research and Development Expense (TTM) Benchmarks
Biomarin Pharmaceutical Inc | 779.92M |
Arbutus Biopharma Corp | 62.79M |
GlycoMimetics Inc | 22.89M |
Cidara Therapeutics Inc | 70.46M |
Cue Biopharma Inc | 40.49M |